McGill University
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1821-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mcgill.ca
Clinical Trials
246
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (219 trials with phase data)• Click on a phase to view related trials
Virtual Reality for Post-Stroke Gait Rehabilitation
- Conditions
- Stroke
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- McGill University
- Target Recruit Count
- 40
- Registration Number
- NCT07201974
- Locations
- 🇨🇦
Jewish Rehabilitation Hospital, Laval, Quebec, Canada
Feasibility of Real-Time Visual Feedback in Augmented Reality to Reduce Gait Asymmetry Post-Stroke
- Conditions
- Stroke
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- McGill University
- Target Recruit Count
- 20
- Registration Number
- NCT07178535
- Locations
- 🇨🇦
Jewish Rehabilitation Hospital - CISSS Laval, Laval, Quebec, Canada
Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal
- Conditions
- Digestive HealthGastrointestinal Health
- Interventions
- Other: Placebo
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- McGill University
- Target Recruit Count
- 4
- Registration Number
- NCT07142486
- Locations
- 🇨🇦
McGill University, Montreal, Quebec, Canada
Effect of Music on Surgical Performance During Artificial Intelligence-Based Simulation Training
- Conditions
- Surgical Education
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- McGill University
- Target Recruit Count
- 40
- Registration Number
- NCT07111481
- Locations
- 🇨🇦
Neurosurgical Simulation and Artificial Intelligence Learning Centre, Montreal, Quebec, Canada
Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada
- Conditions
- HCVHEPATITIS C VIRUS CHRONIC INFECTION
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- McGill University
- Target Recruit Count
- 300
- Registration Number
- NCT07095192
- Locations
- 🇨🇦
Anonyme L'Unite D'Intervention, Montreal, Quebec, Canada
🇨🇦McGill University, Montréal, Quebec, Canada
🇨🇦Indigenous Health Centre of Tiohtià:ke, Montréal, Quebec, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 48
- Next
News
Epitopea's CryptoMap Platform Identifies Novel Immunotherapy Targets in Melanoma and NSCLC
Epitopea's CryptoMap platform identified 589 non-redundant tumor antigens in cutaneous melanoma and NSCLC, with only 1% derived from mutated sequences.
Novel Nucleus Pulposus Allograft Shows Promise for Chronic Back Pain Treatment
Clinical trials of VIA Disc NP, a minimally invasive treatment using donor nucleus pulposus tissue, demonstrated significant reduction in chronic back pain from 7.1 to 3.8 on a 10-point scale over 12 months.
Lecanemab's Effectiveness for Alzheimer's May Be Significantly Lower in Female Patients, Study Suggests
• Recent analysis of lecanemab (Leqembi) clinical trial data reveals a 31% difference in drug effectiveness between male and female Alzheimer's patients, with men showing a 43% slowing of cognitive decline compared to just 12% in women. • Researchers from McGill University conducted 10,000 simulated trials based on Phase 3 CLARITY AD data, finding the gender disparity occurred randomly in only 12 simulations, suggesting the difference is statistically meaningful. • The findings have significant implications for clinical practice as two-thirds of Alzheimer's patients are female, highlighting the urgent need for sex-specific considerations in both drug development and treatment decisions.
Study Reveals 16% of Phase 2 Cancer Trial Patients Receive Eventually FDA-Approved Drugs
A comprehensive analysis of 2,730 phase 2 cancer trials shows that one in six patients receives treatments that ultimately gain FDA approval, providing important insights for clinical trial recruitment.